

# **Bioworld Technology, Inc.**

# Recombinant Human beta-Defensin 4 (rHuBD-4)

Catalog Number: PR1010 Sou

Source: Escherichia coli.

Quantity:5µg/20µg/1.0mg

# Description

Defensins (alpha and beta) are cationic peptides with a broad spectrum of antimicrobial activity that comprise an important arm of the innate immune system. The  $\alpha$ -defensins are distinguished from the  $\beta$ -defensins by the pairing of their three disulfide bonds. To date, four human  $\beta$ -defensins have been identified; BD-1, BD-2, BD-3 and BD-4. The  $\beta$ -defensin proteins are expressed as the C-terminal portion of precursors and are released by proteolytic cleavage of a signal sequence.  $\beta$ -defensins contain a six-cysteine motif that forms three intra-molecular disulfide bonds.  $\beta$ -defensins are 3-5 kDa peptides ranging in size from 33-47 amino acid residues. BD-4 is expressed in testis, stomach, uterus, neutrophils, thyroid, lung and kidney. In addition to its direct antimicrobial activities, BD-4 is chemoattractant towards human blood monocytes.

## **Molecular Weight:**

Approximately 6.0 KDa, a single non-glycosylated polypeptide chain containing 50 amino acids.

## **Purity:**

>98% by SDS-PAGE and HPLC analyses.

#### **Biological Activity:**

Determined by its ability to chemoattract human monocytes using a concentration range of 0.1-100.0 ng/ml, corresponding to a Specific Activity of  $\Box 1 \ge 104$  IU/mg.

#### **Physical Appearance:**

Sterile Filtered White lyophilized (freeze-dried) powder.

# Lyophilized from a 0.2 □ m filtered concentrated solution in 20mM PB, pH 7.4, 130mM NaCl.

#### AA Sequence:

**Formulation:** 

# E F E L D R I C G Y G T A R C R K K C R S Q E Y R I G R C P N T Y A C C L R K W D E S L L N R T K P

#### **Endotoxin:**

Less than  $1EU/\Box g$  of rHuBD-4 as determined by LAL method.

#### **Reconstitution:**

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at <-20 $\Box$ C. Further dilutions should be made in appropriate buffered solutions.

# Storage:

This lyophilized preparation is stable at  $2-8 \square C$ , but should be kept at  $-20 \square C$  for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at  $2-8 \square C$ . For maximal stability, apportion the reconstituted preparation into working aliquots and store at  $-20 \square C$  to  $-70 \square C$ . Avoid repeated freeze/thaw cycles.

## Usage:

This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. Made in China

## Bioworld Technology, Inc.

1660 South Highway 100, Suite 500 St. Louis Park,MN55416,USA.Tel: 6123263284Fax: 6122933841

MADE IN CHINA Bioworld technology, co, Ltd. No 9, weidi road Qixia District Nanjing, 210046, P, R.China. Email: info@biogot.com Tel: 0086-025-86371664 Fax:0086-025-86213570